Overview
Liesbeth Ceelen is the chief executive officer of Biolizard, based in Ghent. She joined the company in November 2019 as director of business development and board member, became general manager and board member in November 2020, and took up the role of CEO in November 2021.
She has run Ceelen Consultancy as an independent consultant since 2013, and holds advisory board roles at Novalis Biotech Incubation, BIO INX and the Stad Gent Entrepreneurship Council. She is a board member of RheumaFinder, a task leader in REPO4EU, a mentor with biotope by VIB and an associate member of Women on Board Belgium. From 2021 to 2023 she was a director at large for marketing and communications with the Healthcare Businesswomen's Association in Brussels.
Earlier she was chief business officer at Pathomation, head of sales and key account manager at Biogazelle, business developer at Vision4Care, and worked at MindCapture and at Anacura, where she was business innovation manager and platform leader for histopathology and molecular diagnostics. She was a technical auditor for BELAC, a post-doctoral assistant at the Vrije Universiteit Brussel and a study director for preclinical safety studies at Janssen Pharmaceutica/J&J.
Ceelen studied veterinary medicine at the University of Antwerp and Ghent University, where she completed a PhD, and holds an Executive MBA from Vlerick Business School.
Career history
In the news
- Chief Executive Officer Marc Dechamps will be speaking at the 4𝐭𝐡 𝐁𝐞𝐧𝐞𝐥𝐮𝐱 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦, bringing together leaders from biotech, pharma, investment and innovation to discuss the future of drug development. This year's theme,"𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐭𝐡𝐞 𝐖𝐚𝐲 𝐖𝐞 𝐓𝐡𝐢𝐧𝐤", will explore new perspectives on advancing drug development and translating scientific innovation into therapies that can benefit patients. At Bioxodes, we are applying that mindset to intracerebral
- Liesbeth Ceelen, CEO van BioLizard: ‘Met enkele regels code alleen kom je er niet’Artificiële intelligentie bracht BioLizard de afgelopen twee jaar in een stroomversnelling. De kmo schoof een eind op van een consultancy- naar een techbedrijf, breidde zijn activiteiten uit naar nieuwe sectoren en stoomt zich klaar voor de Aziatische markt. Artificiële intelligentie bracht dan wel groei, maar dompelt de sector ook in onzekerheid. The post Liesbeth Ceelen, CEO van BioLizard: ‘Met
- Why we don’t celebrate 𝙦𝙪𝙞𝙘𝙠 𝙬𝙞𝙣𝙨... In many tech circles, the biggest applause goes to the fastest team. The overnight prototype. The “we hacked this together in a weekend” moment. But in our world, the world of pharma and biotech, quick wins can become long‑term liabilities. We don’t celebrate speed → We celebrate 𝙨𝙩𝙖𝙗𝙞𝙡𝙞𝙩𝙮. We celebrate 𝙩𝙧𝙖𝙘𝙚𝙖𝙗𝙞𝙡𝙞𝙩𝙮. We celebrate software that still works flawlessly two years later. We celebrate the quiet victories: ⭐︎ The bug that never made it to production. ⭐︎ The
- I’ll be attending ChinaBio soon. Happy to connect and discuss how BioLizard helps translate complex biological data into actionable insights for R&D & clinical teams. Let me know if you’ll be there 🙂 . #ChinaBio #biotech #AI
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.